|
1
|
Chau I, Norman AR, Cunningham D, Waters
JS, Oates J and Ross PJ: Multivariate prognostic factor analysis in
locally advanced and metastatic esophago-gastric cancer--pooled
analysis from three multicenter, randomized, controlled trials
using individual patient data. J Clin Oncol. 22:2395–2403. 2004.
View Article : Google Scholar
|
|
2
|
Miller AB, Hoogstraten B, Staquet M and
Winkler A: Reporting results of cancer treatment. Cancer.
47:207–214. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Comis RL and Carter SK: A review of
chemotherapy in gastric cancer. Cancer. 34:1576–1586. 1974.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kaufman S: 5-Fluorouracil in the treatment
of gastrointestinal neoplasia. N Engl J Med. 288:199–201. 1973.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Moertel CG, Rubin J, O’Connell MJ, Schutt
AJ and Wieand HS: A phase II study of combined 5-fluorouracil,
doxorubicin, and cisplatin in the treatment of advanced upper
gastrointestinal adenocarcinomas. J Clin Oncol. 4:1053–1057.
1986.PubMed/NCBI
|
|
6
|
Wils J, Bleiberg H, Dalesio O, Blijham G,
Mulder N, Planting A, Splinter T and Duez N: An EORTC
Gastrointestinal Group evaluation of the combination of sequential
methotrexate and 5-fluorouracil, combined with adriamycin in
advanced measurable gastric cancer. J Clin Oncol. 4:1799–1803.
1986.
|
|
7
|
Preusser P, Wilke H, Achterrath W, Fink U,
Lenaz L, Heinicke A, Meyer J, Meyer HJ and Buente H: Phase II study
with the combination etoposide, doxorubicin, and cisplatin in
advanced measurable gastric cancer. J Clin Oncol. 7:1310–1317.
1989.PubMed/NCBI
|
|
8
|
Lacave AJ, Barón FJ, Antón LM, Estrada E,
De Sande LM, Palacio I, Esteban E, Gracia JM, Buesa JM, Fernández
OA, et al: Combination chemotherapy with cisplatin and
5-fluorouracil 5-day infusion in the therapy of advanced gastric
cancer: a phase II trial. Ann Oncol. 2:751–754. 1991.PubMed/NCBI
|
|
9
|
Boku N, Yamamoto S, Fukuda H, Shirao K,
Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu
J and Ohtsu A; Gastrointestinal Oncology Study Group of the Japan
Clinical Oncology Group: Fluorouracil versus combination of
irinotecan plus cisplatin versus S-1 in metastatic gastric cancer:
a randomised phase 3 study. Lancet Oncol. 10:1063–1069. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Koizumi W, Narahara H, Hara T, Takagane A,
Akiya T, Takagi M, Miyashita K, et al: S-1 plus cisplatin versus
S-1 alone for first-line treatment of advanced gastric cancer
(SPIRITS trial): a phase III trial. Lancet Oncol. 9:215–221. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sugarbaker PH, Stuart OA, Vidal-Jove J,
Pessagno AM and DeBruijn EA: Pharmacokinetics of the
peritoneal-plasma barrier after systemic mitomycin C
administration. Cancer Treat Res. 82:41–52. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Aznavoorian S, Murphy AN,
Stetler-Stevenson WG and Liotta LA: Molecular aspects of tumor cell
invasion and metastasis. Cancer. 71:1368–1383. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Oshima T, Yamada R, Hatori S, Kunisaki C
and Imada T: Pharmacokinetics of S-1 in patients with peritoneal
dissemination of gastric cancer. Oncol Rep. 16:361–366.
2006.PubMed/NCBI
|
|
14
|
Mori T, Fujiwara Y, Yano M, et al:
Prevention of peritoneal metastasis of human gastric cancer cells
in nude mice by S-1, a novel oral derivative of 5-Fluorouracil.
Oncology. 64:176–182. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yoshida K, Ninomiya M, Takakura N, et al:
Phase II study of docetaxel and S-1 combination therapy for
advanced or recurrent gastric cancer. Clin Cancer Res.
12:3402–3407. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yoshida K, Hirabayashi N, Takiyama W, et
al: Phase I study of combination therapy with S-1 and docetaxel
(TXT) for advanced or recurrent gastric cancer. Anticancer Res.
24:1843–1851. 2004.PubMed/NCBI
|
